Evidence map›Paper›PMID 26817584›Full record

ArticleJournal of experimental & clinical cancer research : CR2016

MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells.

Yang Liu, Yumei Li, Rui Wang, Shukui Qin, Jing Liu, Fang Su, Yan Yang, Fuyou Zhao, Zishu Wang, Qiong Wu

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 89 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. The lncRNA HOTAIR: a pleiotropic regulator of epithelial cell plasticity.Journal of experimental & clinical cancer research : CR · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. miR-224 Regulates the Aggressiveness of Hepatoma Cells Through the IL-6/STAT3/SMAD4 Pathway.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yang LiuDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Yumei LiDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Rui WangDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Shukui QinDepartment of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, Jiangsu, China.
Jing LiuDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Fang SuDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Yan YangDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Fuyou ZhaoDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Zishu WangDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Qiong WuDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China. qiongwu68@outlook.com.
First Affiliated Hospital of Bengbu Medical College · CN81th Hospital of PLA · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEmerging evidence demonstrates that microRNAs (miRNAs) play an important role in regulation of cell growth, invasion and metastasis through inhibiting the expression of their targets. It has been reported that miR-130a-3p controls cell growth, migration and invasion in a variety of cancer cells. However, it is unclear whether miR-130a-3p regulates epithelial-mesenchymal transition (EMT) in drug resistant cancer cells. Therefore, in the current study, we explore the role and molecular mechanisms of miR-130a-3p in gemcitabine resistant (GR) hepatocellular carcinoma (HCC) cells.

methodsThe real-time RT-PCR was used to measure the miR-130a-3p expression in GR HCC cells compared with their parental cells. The wound healing assay was conducted to determine the cell migratory activity in GR HCC cells treated with miR-130a-3p mimics. The migration and invasion assays were also performed to explore the role of miR-130a-3p in GR HCC cells. Western blotting analysis was used to measure the expression of Smad4, E-cadherin, Vimentin, and MMP-2 in GR HCC cells after depletion of Smad4. The luciferase assay was conducted to validate whether Smad4 is a target of miR-130a-3p. The student t-test was used to analyze our data.

resultsWe found the down-regulation of miR-130a-3p in GR HCC cells. Moreover, we validate the Smad4 as a potential target of miR-130a-3p. Furthermore, overexpression of miR-130a-3p suppressed Smad4 expression, whereas inhibition of miR-130a-3p increased Smad4 expression. Consistently, overexpression of miR-130a-3p or down-regulation of Smad4 suppressed the cell detachment, attachment, migration, and invasion in GR HCC cells.

conclusionsOur findings provide a molecular insight on understanding drug resistance in HCC cells. Therefore, activation of miR-130a-3p or inactivation of Smad4 could be a novel approach for the treatment of HCC.

Indexed as

Drug Resistance, NeoplasmCarcinoma, HepatocellularCell Line, TumorCell MovementDeoxycytidineEpithelial-Mesenchymal TransitionGemcitabineGene Expression Regulation, NeoplasticHep G2 CellsHumansLiver NeoplasmsMicroRNAsNeoplasm InvasivenessSmad4 ProteinDeoxycytidineGemcitabineMicroRNAsMIRN130 microRNA, humanSmad4 ProteinSMAD4 protein, human

Identifiers

PMID26817584
PMCPMC4729098
OpenAlexW2305271175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.